Richard Adcock

Chief Executive Officer at ImmunityBio

Board

Since October 20, 2020

Age

56 years

Education

Holds a Bachelor of Science in Business Administration from Northern State University and an MBA in Healthcare Management from the University of Phoenix.

Tenure

Joined IBRX as Chief Executive Officer on October 20, 2020 and was later appointed President and Board member in March 2021.

Also at ImmunityBio

Patrick Soon-Shiong

Executive Chairman of the Board

David Sachs

Chief Financial Officer (CFO)

About

Richard Adcock is a seasoned executive in the healthcare industry, currently serving as the Chief Executive Officer of IBRX since October 2020, and is 56 years old as of April 29, 2025.

He holds a Bachelor of Science in Business Administration from Northern State University and an MBA in Healthcare Management from the University of Phoenix, forming the foundation of his extensive career in healthcare management.

Prior to IBRX, he held pivotal roles including Global Engineering Director at GE Healthcare, and executive positions at Sanford Health and Verity Health System, demonstrating his expertise in operational leadership and strategic innovation. His appointment as President and Board member in March 2021 further reflects his significant contributions to organizational growth.

$IBRX Performance Under Richard Adcock

Past Roles

Organization	Role	Date Range	Details
ImmunityBio, Inc. (IBRX)	Board Member	March 2021	Former role held at IBRX
ImmunityBio, Inc. (IBRX)	President	N/A	Former role held at IBRX
Verity Health System of California, Inc.	Chief Executive Officer	January 2018 - September 2020	Steered the organization through a restructuring event
Sanford Health	Chief Innovation Officer / President / Executive Vice President / Director	2004 - 2017	Held various leadership roles
GE Healthcare	Global Engineering Director	N/A	N/A

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Salary	$802,123	Annual	Base salary for 2024 including any salary increases
Stock Awards	$2,396,341	457,317 RSUs awarded on February 22, 2024 vesting in three equal annual installments (33.33%, 33.33%, 33.34%)	Grant date fair value of RSUs
Option Awards	$7,214,767	1,591,463 options granted on February 22, 2024 vesting in three equal annual installments (33.33%, 33.33%, 33.34%)	Exercise price $5.24 per share
All Other Compensation	$64,044	As applicable	Includes $14,045 for 401(k) contributions and $49,999 for life insurance premium reimbursements with tax neutrality

Performance Compensation

Data from FY 2024

Performance Compensation: Non-Equity Incentive Plan Compensation for 2024

Component	Description/Value	Details
Target Bonus Opportunity	$597,000	Calculated as 75% of the annual base salary of $796,000
Actual Bonus Payout	$477,600	Achieved at 80.0% of the target bonus based on performance metrics
Performance Metrics	N/A	Includes categories: Financing, Regulatory & Product, Clinical Development, Commercial Readiness, and Human Capital
Evaluation Period	Fiscal Year 2024	Performance measured for the 2024 period
Vesting/Payment	No vesting schedule; cash award paid in 2025	Contingent upon achievement of performance metrics and continued employment
Grant Date	February 22, 2024	Applies to the performance compensation framework
Grant Date Stock Price	$5.24 per share	Provided for reference though not applicable to the cash award
Bonus Parameters	No threshold or cap defined	The bonus plan did not specify a maximum payout